|
|
Vaccine Detail
|
Melapuldencel-T Vaccine |
| Vaccine Information |
- Vaccine Name: Melapuldencel-T Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007524
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Description: A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, melapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes. (NCIT_C120183).
|
| Host Response |
|
|
| References |
NCIT_C120183: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120183]
|
|
